Skip to main content
GERN logo

GERN · Geron Corp

Track GERN — free
$1.53 -0.02 (-1.29%) At close · Aug 26
Market Cap
$995.83M
Shares
642.47M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.53 Open$1.58 Day$1.50–1.58 52W close$1.07–1.95 Avg vol 30d9.9M Short int80.6M · 12.5% float · 5.8d Short vol40% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 15.2 · calm Equity put/call 0.64
      Technical
      price trend
      Neutral
      50 / 200-day cross Golden cross
      Price vs 200-day avg +7%
      above
      Price vs 50-day avg +7%
      above
      RSI (14) 53
      neutral
      MACD trend Negative
      52-week position 52%
      mid-range
      Volume (OBV) Bearish div.
      distributing
      Momentum
      relative strength
      Strong
      1-month return +9%
      trailing
      6-month return +8%
      trailing
      YTD return +16%
      this year
      Relative strength −5%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) Golden cross
      50d $1 › 200d $1 — 50d above 200d
      Institutional flow Accumulating
      +1% holders QoQ · +37 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      12.55% of float · ▲ +4.9% MoM · 5.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      259 holders — mid 3-yr range
      Squeeze score 75
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth −83%
      Y/Y
      EPS growth +52%
      Y/Y
      Free cash flow $-111.7M
      Balance sheet $42.0M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 64%
      annualized · 1-yr
      Max drawdown −44%
      past year
      ATR 5.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 6, 2026
      RYTELO net product revenue · fiscal year 2026 Initiated $220M – $240M
      Total operating expenses · fiscal year 2026 Initiated $230M – $240M
      Prior guidance period ended · from the 8-K filed Nov 5, 2025
      Total operating expenses · fiscal year 2025 $250M – $260M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 2 · 3
      50 / 200-day cross
      Golden cross Bullish
      Price vs 200-day avg
      +7% Bullish
      Price vs 50-day avg
      +7% Bullish
      RSI (14)
      53 Neutral
      MACD trend
      Negative Bearish
      52-week position
      52% Neutral
      Volume (OBV)
      Bearish div. Bearish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) Golden cross
      50d $1 › 200d $1 — 50d above 200d
      Institutional flow Accumulating
      +1% holders QoQ · +37 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      12.55% of float · ▲ +4.9% MoM · 5.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      259 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $1 Now $2 · 52% Range high $2
      vs 200-day avg +7% vs 50-day avg +7% 50-day above 200-day golden cross

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Ordering accounts added 150 Q4 2025
      RYTELO demand growth 9% Q4 2025 vs Q3 2025

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GERN
      Geron Corp
      this stock
      $995.83M +15.9% -82.7% 12.5%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $138.72B +20.7% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $83.89B +5.6% +20.8% 20.2 2.3%
      ARGX
      Argenx SE
      $63.81B +24.5% 1.9%
      CSLLY
      Csl Ltd
      $60.07B 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      259
      % held
      74.4%
      Net QoQ
      -21.5M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      132
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      80.6M
      Days to cover
      5.8d
      Change
      +3.8M sh
      View
      Short Volume
      Short vol %
      40%
      As of
      Aug 26, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      580
      Value
      $824
      As of
      Jul 16, 2026
      View
      Off-Exchange
      Off-exchange %
      49.3%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $237.0K
      Net income (FY)
      $-83.5M
      EPS diluted
      $-0.13
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $27.4K
      Shares
      20.0K
      Filed
      Dec 15, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      GERN -3.8% +9.3% +7.8% +18.6% +15.9%
      SPY -0.4% +5.0% +12.4% +2.6% +12.3%
      vs SPY -3.4% +4.3% -4.7% +16.1% +3.6%
      Key facts CIK 886744 CUSIP 374163103 13F (30d) 217 filings 215 filers Visit website Investor relations